London: AstraZeneca Its blockbuster cancer drug on Tuesday said, ImfinziFailed to improve disease free life one of final stage testing to treat a type of early stage lung cancer,

Imfinzi is a human monoclonal antibody that works by blocking a tumor’s ability to evade and subdue the immune system, boosting the body’s anti-cancer immune response, as an alternative to chemotherapy.

Adjuvant BR.31 The phase III trial could not meet the primary endpoint of disease-free survival compared with placebo in patients with early-stage non-small-cell lymphoma. lung cancer after tumor removal in patients whose tumors have expression PD-L1 The drug manufacturer said the drug affects 25 percent or more of tumor cells.

“We are disappointed with the results for adjuvant BR.31,” said Suzanne Galbraith, executive vice president of oncology research and development at AstraZeneca.

The latest results contrast with those published in April, when the Anglo-Swedish drugmaker said Imfinzi, in a separate trial, helped improve the chances of survival for patients with early-stage small-cell or aggressive types of lung cancer, meeting two key trial goals.

(Reporting by Yadrisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)